Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 4Neoplasms 2Lymphoma, Non-Hodgkin 2Recurrence 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Hematologic Neoplasms 1Hematologic Diseases 1Glioblastoma 1Carcinoma 1

Interventions

Brentuximab Vedotin 21Cyclophosphamide 17Rituximab 11fludarabine 9Mycophenolic Acid 9pirtobrutinib 7dacetuzumab 7Busulfan 7fludarabine phosphate 6Tacrolimus 6Melphalan 6Whole-Body Irradiation 5Doxorubicin 5Vincristine 4Prednisone 4Mesna 4Etoposide 4Bone Marrow Transplantation 4Bendamustine Hydrochloride 4ibrutinib 3Thiotepa 3Sirolimus 3Cyclosporine 3Bortezomib 3ponatinib 2Vorinostat 2Stem Cell Transplantation 2Rifampin 2Platelet Transfusion 2Peripheral Blood Stem Cell Transplantation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Diseases × Ketoconazole × Lymphoid × Clear all
NCT01026415 2014-12-18

Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)

Seagen Inc.

Phase 1 Completed
73 enrolled
Lymphoid

Carcinoma, Hematologic Diseases, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Neoplasms, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡